{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:46:43Z","timestamp":1792291603123,"version":"4.4.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.jad.2023.04.141","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T03:49:26Z","timestamp":1684208966000},"page":"484-492","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"special_numbering":"C","title":["The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis"],"prefix":"10.1016","volume":"335","author":[{"given":"Tuuli M.","family":"Hietamies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Alison","family":"McInnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Klise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Worley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy J.","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne M.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris D.","family":"Heifets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jad.2023.04.141_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.jad.2023.04.141_bb0010","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s12888-022-04268-5","article-title":"Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: a retrospective descriptive cohort study","volume":"22","author":"Ahuja","year":"2022","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.jad.2023.04.141_bb0015","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jpsychires.2022.04.037","article-title":"Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis","volume":"151","author":"Alnefeesi","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.04.141_bb2005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jpsychires.2014.07.027","article-title":"Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety","volume":"58","author":"Ballard","year":"2014","journal-title":"J. Psychiatr. Res."},{"issue":"6942","key":"10.1016\/j.jad.2023.04.141_bb0020","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/bmj.308.6942.1499","article-title":"Regression towards the mean","volume":"308","author":"Bland","year":"1994","journal-title":"BMJ (Clinical research ed.)"},{"key":"10.1016\/j.jad.2023.04.141_bb0025","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"2013"},{"issue":"3","key":"10.1016\/j.jad.2023.04.141_bb0030","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1176\/appi.ajp.2007.06111868","article-title":"Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report","volume":"165","author":"Fava","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.04.141_bb0035","series-title":"Psychiatric Services (Washington, D.C.)","first-page":"1439","article-title":"What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression","volume":"vol. 60(11)","author":"Gaynes","year":"2009"},{"key":"10.1016\/j.jad.2023.04.141_bb0040","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.992624","article-title":"Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use","volume":"13","author":"Hassan","year":"2022","journal-title":"Front. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2023.04.141_bb0045","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1136\/bmjebm-2019-111161","article-title":"Is there a genuine placebo effect in acute depression treatments? A reassessment of regression to the mean and spontaneous remission","volume":"25","author":"Hengartner","year":"2020","journal-title":"BMJ Evidence-based Med."},{"issue":"3","key":"10.1016\/j.jad.2023.04.141_bb0050","doi-asserted-by":"crossref","first-page":"17r11470","DOI":"10.4088\/JCP.17r11470","article-title":"Trajectories of acute antidepressant efficacy: how long to wait for response? A systematic review and meta-analysis of long-term, placebo-controlled acute treatment trials","volume":"79","author":"Henssler","year":"2018","journal-title":"J. Clin. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.04.141_bb0055","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1192\/apt.bp.114.014274","article-title":"Ketamine as a rapid antidepressant: the debate and implications","volume":"22","author":"Ho","year":"2016","journal-title":"BJPsych Adv."},{"key":"10.1016\/j.jad.2023.04.141_bb0060","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.jad.2023.04.141_bb0065","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/bdi.12277","article-title":"A single infusion of ketamine improves depression scores in patients with anxious bipolar depression","volume":"17","author":"Ionescu","year":"2015","journal-title":"Bipolar Disord."},{"issue":"3","key":"10.1016\/j.jad.2023.04.141_bb0070","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","article-title":"Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials","volume":"72","author":"Kryst","year":"2020","journal-title":"Pharmacol. Rep."},{"issue":"7","key":"10.1016\/j.jad.2023.04.141_bb0075","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032895","article-title":"Social determinants and distance from certified treatment centers are associated with initiation of esketamine nasal spray among patients with challenging-to-treat major depressive disorder","volume":"102","author":"Liberman","year":"2023","journal-title":"Medicine"},{"key":"10.1016\/j.jad.2023.04.141_bb0080","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.jad.2021.12.097","article-title":"A retrospective analysis of ketamine intravenous therapy for depression in real-world care settings","volume":"301","author":"McInnes","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"8","key":"10.1016\/j.jad.2023.04.141_bb0085","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bdi.12941","article-title":"The effectiveness of ketamine on anxiety, irritability, and agitation: implications for treating mixed features in adults with major depressive or bipolar disorder","volume":"22","author":"McIntyre","year":"2020","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2023.04.141_bb0090","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.jad.2020.05.088","article-title":"The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: results from the Canadian Rapid Treatment Center of Excellence","volume":"274","author":"McIntyre","year":"2020","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.jad.2023.04.141_bb0095","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1176\/appi.ajp.2020.20081251","article-title":"Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: an international expert opinion on the available evidence and implementation","volume":"178","author":"McIntyre","year":"2021","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2023.04.141_bb0100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.biopsych.2012.06.022","article-title":"Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression","volume":"74","author":"Murrough","year":"2013","journal-title":"Biol. Psychiatry"},{"issue":"16","key":"10.1016\/j.jad.2023.04.141_bb0105","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1017\/S0033291715001506","article-title":"Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial","volume":"45","author":"Murrough","year":"2015","journal-title":"Psychol. Med."},{"issue":"6","key":"10.1016\/j.jad.2023.04.141_bb0110","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1080\/14740338.2022.2066651","article-title":"Long-term safety of ketamine and esketamine in treatment of depression","volume":"21","author":"Nikayin","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"issue":"6","key":"10.1016\/j.jad.2023.04.141_bb0115","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.21m14336","article-title":"Clinical effectiveness of intravenous racemic ketamine infusions in a large community sample of patients with treatment-resistant depression, suicidal ideation, and generalized anxiety symptoms: a retrospective chart review","volume":"83","author":"Oliver","year":"2022","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2023.04.141_bb0120","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1176\/appi.ajp.2018.18070834","article-title":"Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: a randomized controlled trial","volume":"176","author":"Phillips","year":"2019","journal-title":"Am. J. Psychiatry"},{"issue":"8","key":"10.1016\/j.jad.2023.04.141_bb0130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1080\/14740338.2020.1776699","article-title":"Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence","volume":"19","author":"Rodrigues","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"issue":"3","key":"10.1016\/j.jad.2023.04.141_bb0135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/da.22875","article-title":"Efficacy of intravenous ketamine treatment in anxious versus nonanxious unipolar treatment-resistant depression","volume":"36","author":"Salloum","year":"2019","journal-title":"Depression Anxiety"},{"issue":"8","key":"10.1016\/j.jad.2023.04.141_bb0140","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1176\/appi.ajp.2016.16010037","article-title":"A double-blind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression","volume":"173","author":"Singh","year":"2016","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2023.04.141_bb0145","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1176\/appi.ajp.2017.17040472","article-title":"The effect of a single dose of intravenous ketamine on suicidal ideation: a systematic review and individual participant data Meta-analysis","volume":"175","author":"Wilkinson","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.04.141_bb0150","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1745-6215-12-4","article-title":"International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol","volume":"12","author":"Williams","year":"2011","journal-title":"Trials"},{"issue":"1","key":"10.1016\/j.jad.2023.04.141_bb2000","first-page":"9","volume":"2","author":"Yavi","year":"2022","journal-title":"Ketamine treatment for depression: a review. Discover mental health"},{"issue":"4","key":"10.1016\/j.jad.2023.04.141_bb0155","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/0269881119827811","article-title":"Investigation of medical effect of multiple ketamine infusions on patients with major depressive disorder","volume":"33","author":"Zheng","year":"2019","journal-title":"J. Psychopharmacol. (Oxford, England)"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723006110?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723006110?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T04:13:55Z","timestamp":1759032835000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723006110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":32,"alternative-id":["S0165032723006110"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.04.141","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effects of ketamine on symptoms of depression and anxiety in real-world care settings: A retrospective controlled analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.04.141","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}